本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Cartesian Therapeutics

6.41
+0.01000.16%
盤後6.540.1300+2.03%19:14 EST
成交量:13.45萬
成交額:84.64萬
市值:1.67億
市盈率:-3.42
高:6.56
開:6.41
低:6.08
收:6.40
52周最高:20.00
52周最低:5.98
股本:2,600.36萬
流通股本:939.03萬
量比:1.37
換手率:1.43%
股息:- -
股息率:- -
每股收益(TTM):-1.8750
每股收益(LYR):-4.4814
淨資產收益率:-7029.26%
總資產收益率:-12.67%
市淨率:-4.65
市盈率(LYR):-1.43

資料載入中...

公司資料

公司名字:
Cartesian Therapeutics
交易所:
NASDAQ
成立時間:
- -
員工人數:
66
公司地址:
7495 New Horizon Way,Frederick,Maryland,United States
郵編:
21703
電話:
傳真:
- -
簡介:
Cartesian Therapeutics, Inc.在特拉華州成立。該公司是一家臨床階段的公司,開創了治療自身免疫性疾病的RNA細胞療法。該公司的主要資產Descartes-08是一種潛在的first-in-class、RNA工程嵌合抗原受體T細胞療法(rCAR-T),正處於全身性重症肌無力患者的2b期臨床開發階段,並計劃在系統性紅斑狼瘡以及眼部自身免疫和血管性自身免疫籃子試驗中開展額外的2期研究。Cartesian在馬里蘭州蓋瑟斯堡經營一家全資擁有的最先進的cGMP生產設施。

董事

名稱
職位
Carsten Brunn
Chairman,President and Chief Executive Officer
Patrick Zenner
Lead Independent Director
Adrian Bot
Director
Kemal Malik
Director
Michael Singer
Director
Murat Kalayoglu
Director
Nishan de Silva
Director
Timothy A. Springer
Director
Timothy C. Barabe
Director

股東

名稱
職位
Carsten Brunn
Chairman,President and Chief Executive Officer
Blaine Davis
Chief Financial Officer
Christopher Jewell
Chief Scientific Officer
Emily English
Chief Operations Officer
June Seymour
Chief Accounting Officer
Metin Kurtoglu
Chief Technology Officer
Milos Miljkovic
Chief Medical Officer